These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32063102)

  • 1. Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
    Yassine D; Brown EN; Putney D; Fasoranti O
    J Oncol Pharm Pract; 2020 Oct; 26(7):1650-1656. PubMed ID: 32063102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
    Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
    Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
    Hedvat J; Howlett C; McCloskey J; Patel R
    J Thromb Thrombolysis; 2018 Nov; 46(4):483-487. PubMed ID: 30191357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
    Dawwas GK; Brown J; Dietrich E; Park H
    Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
    Davis DO; Davis KA
    J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.
    Sarratt SC; Nesbit R; Moye R
    Ann Pharmacother; 2017 Jun; 51(6):445-450. PubMed ID: 28478715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Stepien K; Nowak K; Zalewski J; Pac A; Undas A
    Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series.
    DeCamillo D; Ellsworth S; Kaatz S; Barnes GD
    J Thromb Thrombolysis; 2020 Nov; 50(4):844-848. PubMed ID: 32219722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.
    Fredman D; McNeil R; Eldar O; Leader A; Gafter-Gvili A; Avni T
    J Thromb Thrombolysis; 2024 Mar; 57(3):453-465. PubMed ID: 38127261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
    Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study.
    Glise Sandblad K; Schulman S; Rosengren A; Sörbo J; Philipson J; Hansson PO
    J Intern Med; 2023 Dec; 294(6):743-760. PubMed ID: 37641391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.